FLUBENCUR™ is a broad-based nutraceutical formula containing Flubendazole, Curcumin extract and other nutrients which have been shown to initiate cell death (apoptosis) in mutagenic cells and in particular Flubendazole has been shown to target breast tumor stem-like cells and initiate autophagic cell death via STAT3. So far flubendazole has sparked interest for use in selected human malignant cells including myeloma, leukemia, neuroblastoma, breast tumors, colorectal tumors and melanoma (PDF).
Note For our FENBENDAZOLE-based FENBENCUR™ item, see here.
FLUBENCUR™ capsules each contain 38mg (99.2% purity) Flubendazole (FLB), Curcumin Longa, Berberine, Green Tea Extract, Quercetin, Ginger Extract & Black Pepper. The 4 capsule (every-other-day) dosage takes it’s cue’s from a 2019 Flubendazole study on mice colon tumors at Wenzhou Medical University, China and includes some supportive co-factors listed above which increase ER Stress / Free Radicals (ROS) and may inhibit DHFR within the cells. Inhibiting DHFR has an Anti-folate effect similar to using 5FU which was found to enhance the anti-tumor effects of Flubendazole in the 2019 study.
It is suggested that capsules are taken every other day as per the study above, this ‘pulsing’ is believed to exert maximum stress on tumors.
Treatment with flubendazole caused no obvious change in total STAT3 expression, but it strongly reduced the expression of phosphorylated STAT3 (P-STAT3) in a dose and time-dependent manner . Flubendazole inhibited STAT3 phosphorylation partly dependent of the upstream kinases JAK2 and JAK3. Together, these results confirmed that flubendazole may suppress tumor progression by inactivating and/or inhibiting the expression of JAK/STAT3 signaling and STAT3-associated target genes. Flubendazole induces autophagy initiation by inactivating mTOR and P62, and upregulating LC3-I/II. Flubendazole is a well-known anthelmintic drug that is widely used to treat infections of worm and intestinal parasites in clinical practice. The anthelmintic action of flubendazole is based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function . Notably, other research groups have suggested that flubendazole is a potential antitumor agent . In the 2019 study flubendazole inhibited CRC cells proliferation in a concentration dependent manner, but correspondingly has weak inhibitory effect to normal human cells at the concentrations used the study. Accordingly, the treatment with flubendazole appears to be safe to normal cells and powerfully cytotoxic to CRC cells.
FLUBENCUR™ is taken twice a day and pulsed every other day. A pack of 60 vegan capsules can last for 30 days.
Supportive Fluben Items
For other dietary suggestions, see the BiohackIT phone app at https://werone.co/biohackit
Apoptosis inducers cause tumor cells to undergo a process of controlled cell death called apoptosis. Apoptosis is one method the body uses to get rid of unneeded or abnormal cells, but tumor cells have strategies to avoid apoptosis. Apoptosis inducers can get around these strategies to cause the death of tumor cells. Angiogenesis inhibitors block the growth of new blood vessels to tumors (a process called tumor angiogenesis).
A blood supply is necessary for tumors to grow beyond a certain size because blood provides the oxygen and nutrients that tumors need for continued growth. Treatments that interfere with angiogenesis may block tumor growth. Some targeted therapies that inhibit angiogenesis interfere with the action of vascular endothelial growth factor (VEGF), a substance that stimulates new blood vessel formation and also fuelled by Glutamine usage which can be inhibited by blocking the cMYC gene pathway and limiting certain proteins such as:
- Red meats (wild caught fish and free range eggs are better in small quantities)
- All dairy products except perhaps cottage cheese
- Wheat (which is rich in glutamine)
- All sugars and sweet fruits.
Tumor cells take up and metabolise glucose and glutamine to a degree that far exceeds their needs for these molecules in anabolic macromolecular synthesis. Commonly occurring oncogenic signal transduction pathways initiated by receptor tyrosine kinases or Ras engaged PI3K-Akt signaling to directly stimulate glycolytic metabolism. Oncogenic levels of Myc have recently been linked to increased glutaminolysis through a coordinated transcriptional program. Myc-activation/amplification is one of the most common oncogenic events observed in mutagenic cells.
FLUBENCUR™ is a broad-based nutraceutical formula containing herbal extracts and other nutrients which have been shown to provide antitumor support.
FLUBENCUR™ aims to restore P53 tumor supressor and block the pathways which are used for metastasis and to provide immune system support and block glucose pathways which are also used as supplementary food supplies for tumor cells.
FLUBENCUR™ has not been scientifically proven in this respect though it’s individual ingredients have been shown in various studies to be efficacious and safe. All extracts are pharmaceutical grade and contained in an HPMC vegan capsule.
Every other day, take 2 x caps with water in the morning after food and 2 x Caps in the evening after food, pulse FLUBENCUR™ 1 DAY ON / 1 DAY OFF or as directed by your health professional. May be suitable as an adjuvant.
Additionally, in order to block other pathways according to the tumor’s phenotype such as Lipids (fatty acid synthase) and Glutamine (Proteins), we suggest you follow the off-label drugs and nutritional strategies described in Jane McLelland’s Book: ‘How to Starve Cancer’ . Remove all sources of Omega 6 PUFA veg oils and nuts from the diet. [Source] . We are also working on new herbal formulas to help target these pathways (FASNhib™, GLUTAhib™, CASPACT™).
For more dietary resources see BiohackIT app.
Quality Assurance Declaration
Werone.co endeavors to use the most potent source materials within our formulas. Our herbal extracts are sourced and tested by the only Government-certified large scale producer of crude herb (powder-free) TCM concentrates in Asia who manufacture to GMP / ISO 9001/2000 pharmaceutical grade and also operate an ISO17025/TAF-certified laboratory where they subject all plant extracts to strict quality inspections free from heavy metals, pesticides or microbes before release to the clinics all over the world. The formulas and tinctures are assembled without fillers in small batches by a BHMA member herbal dispensary.
Nutraceutical DisclaimerThese statements have not been evaluated by the Food and Drug Administration or MHRA and the items are not intended to diagnose, treat, cure, or prevent any disease nor are they associated, endorsed, affiliated or sponsored by Anthony William, Medical Medium® Joe Tippens or Jim Gordon.
Clinical Studies Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy
https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1303-z  Anthelmintic Flubendazole and its potential use in anticancer therapy. Acta Med (Hradec Kralove). 2017;60(1):5–11.
https://actamedica.lfhk.cuni.cz/60/1/0005/  Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int J Cancer. 2018;143(8):1978–93.
https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31585  Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. Cancer Lett. 2018;412:118–30.
https://www.sciencedirect.com/science/article/abs/pii/S0304383517306572?via%3Dihub  Flubendazole targets processes for activation of autophagy with a broad translational potential
Flubendazole, is a potent inducer of autophagy initiation and flux by affecting acetylated and dynamic microtubules in a reciprocal way. Disruption of dynamic microtubules by flubendazole results in mTOR deactivation and dissociation from lysosomes leading to TFEB (transcription factor EB) nuclear translocation and activation of autophagy. By inducing microtubule acetylation, flubendazole activates JNK1 leading to Bcl-2 phosphorylation, causing release of Beclin1 from Bcl-2-Beclin1 complexes for autophagy induction, thus uncovering a new approach to inducing autophagic flux that may be applicable in disease treatment.
Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway
Citrate exhibits negative feedback on glycolysis2 and on the enzyme pyruvate dehydrogenase3,4 Conversely, inhibition of glycolysis suppresses tumor growth and can contribute to CD8+ T cell maturation28. Therefore, we hypothesized that citrate-mediated AKT inhibition might down regulate glycolysis.
Safety of Flubendazole
Flubendazole has been tested for carcinogenicity in both rats and mice using formulated diet at doses equivalent to a maximum of 20mg/kg in rats and 30mg/kg in mice. Neither showed evidence of carcinogenicity in any tissue including the GI tract (8). Although systemic exposure data were not reported in these tests, separate studies in the Wistar rat, after an oral dose of 40mg/kg, using a microsuspension of flubendazole, showed that after 4h, plasma levels of flubendazole reached 81ng/ml. In a separate study in the same strain given 10mg/kg of a microcrystalline suspension of 14C-labelled flubendazole, plasma levels reached 0.27µg/ml. The amount of total radioactivity present in the liver, lung, kidney, muscle and fat did not exceed 3.1 µg/g of tissue (39). It should be noted that the level observed in plasma after dosing with 10mg/kg of flubendazole is similar to the POD metrics for aneuploidy calculated for this compound in in vitro tests.